The liver is a site of both primary and secondary neoplasia. The prevalence of primary hepatobiliary neoplasia ranges from 0.6% to 2.6% of dogs based on necropsy studies. Secondary tumors of the liver occur more frequently, with metastasis to the liver occurring in 30.6% to 36.8% of dogs with primary nonhepatic neoplasia. Metastasis to the liver is most common from tumors of the spleen, pancreas, and gastrointestinal tract.

The prevalence of primary hepatobiliary tumors in cats has been reported to be 1.5% and 2.3% of cats undergo necropsies. When hematopoietic neoplasms were excluded in one study, 6.9% of tumors were hepatic in origin. Currently, there are no comprehensive studies regarding the prevalence of metastatic liver disease in cats.

**TUMOR TYPES**

Primary hepatobiliary tumors can develop from the hepatocyte (hepatocellular adenoma, hepatocellular carcinoma); bile duct epithelium (biliary adenoma, biliary carcinoma); neuroendocrine cells (neuroendocrine carcinoma or carcinoid); or stromal cells (sarcomas). These can be further characterized based on their morphologic appearance: massive involving a large mass in one lobe, nodular with discrete nodules in several lobes, or diffuse where the entire liver or part of it is infiltrated with neoplastic cells. Other neoplastic conditions that often involve the liver include lymphoma, disseminated histiocytic sarcoma, and systemic mastocytosis.

**AGE, GENDER, AND BREED PREDILECTION**

Hepatobiliary tumors are usually found in older animals between the ages of 9 and 12 years. Carcinoids in dogs are usually diagnosed in slightly younger animals with a mean age of 8 years; this may also be true for cats. Some studies have reported...
more male dogs diagnosed with hepatocellular carcinoma and more male cats with carcinoids and bile duct tumors; other studies have shown no differences between genders. There are no breed predilections in either dogs or cats.

**CLINICAL SIGNS**

**Dogs**

Clinical signs for dogs with hepatobiliary tumors are nonspecific with anorexia, lethargy, vomiting, and weight loss the most common. Other clinical signs reported include polyuria, polydipsia, abdominal distention, diarrhea, jaundice, dyspnea, seizures, myelopathy, hematochezia and melena less frequently. In one study, 5 of 18 dogs had no clinical signs at the time of diagnosis.

**Cats**

Anorexia, lethargy, and vomiting are the most common reported clinical signs in cats. Cats with malignant tumors are more likely to show clinical signs than those with benign tumors.

**PHYSICAL EXAMINATION**

Hepatomegaly or cranial abdominal mass is the most common physical examination abnormality in both dogs and cats. Abdominal pain, ascites, and icterus are less frequent.

**LABORATORY**

**Dogs**

Hematologic and biochemical changes in dogs are common but not specific for liver tumors. Anemia (20%–53%) and leukocytosis (26%–90%) are reported frequently. Forty-six percent of dogs with massive hepatocellular carcinoma had thrombocytosis. Abnormalities in coagulation profiles have been documented in dogs with primary hepatic neoplasia and should be evaluated before invasive procedures. Liver enzymes are commonly elevated but are not specific for the diagnosis of neoplasia. One report showed an association between liver enzyme elevations and prognosis. Other biochemical abnormalities documented include hypoalbuminemia, hyperglobulinemia, hypoglycemia, and elevated bile acids.

**Cats**

As with dogs, cats with hepatobiliary tumors have nonspecific hematologic and biochemical abnormalities. Twenty-eight percent of cats in one study had a leukocytosis. Alanine aminotransferase, aspartate aminotransferase, and total bilirubin were higher in cats with malignant tumors compared with benign tumors in another study but cannot be used to differentiate the two. Cats with neuroendocrine carcinomas of the bile duct or gallbladder are more likely to have liver specific biochemical abnormalities than cats with hepatic neuroendocrine carcinomas. Azotemia was the most common biochemical abnormality in one report but was not characterized as primary renal or other and may be a reflection of the age of the cats at diagnosis (11–14 years).

**PARANEoplastIC SYNDROMES**

Paraneoplastic hypoglycemia has been reported with hepatocellular carcinoma, hepatic leiomyosarcoma, and hemangiosarcoma in dogs. Alopecia has been reported.
reported in cats with hepatocellular and bile duct carcinomas.\textsuperscript{23,24} Thrombocytosis has been documented in 18 of 39 dogs with massive hepatocellular carcinoma and is currently being investigated to determine if this is a paraneoplastic phenomenon.\textsuperscript{12}

**IMAGING**

Abdominal radiographs can be used to detect cranial abdominal masses in dogs and cats; however, ultrasound is the preferred method of imaging.\textsuperscript{12,15,16} Ultrasound allows for the characterization of morphologic features of the tumor (massive, nodular, or diffuse) and also can be used to detect intra-abdominal metastasis. Ultrasound-guided fine-needle aspirate of a liver mass is a minimally invasive procedure that can be helpful in obtaining a diagnosis. Limitations of this diagnostic procedure should be acknowledged because agreement between cytology and histopathology has varied among studies from 14\% to 86\%.\textsuperscript{25,26} Ultrasound-guided needle biopsy is a relatively safe procedure in patients with greater than 50,000/\(\mu\)L platelets and normal coagulation parameters.\textsuperscript{27} Results of needle biopsies for liver tumors correlated with wedge biopsies in 7 of 10 cases in one study.\textsuperscript{28} Three-view thoracic radiographs should be performed to rule out pulmonary metastasis. CT with contrast enhancement and MRI may help in determining the resectability of a tumor (discussed elsewhere in this issue).

**TREATMENT AND PROGNOSIS OF SELECTED TUMOR TYPES**

**Hepatocellular Tumors**

Hepatocellular adenomas are benign tumors found in both dogs and cats (Fig. 1).\textsuperscript{3,11} They are more common than hepatocellular carcinoma in cats\textsuperscript{11} and less common in dogs.\textsuperscript{3} Hepatocellular carcinoma is the most common primary liver tumor in dogs (Fig. 2).\textsuperscript{8} They are classified as massive, nodular, or diffuse. In one study, the majority were massive (61\%), followed by nodular (29\%) and diffuse (10\%).\textsuperscript{8} Liver lobectomy is the treatment of choice for dogs and cats with a solitary massive hepatocellular tumor. In one report of dogs with massive hepatocellular carcinoma, the perioperative mortality rate was 11.9\% (5 of 42) with two dogs dying intraoperatively because of exsanguination; the complication rate was 28.6\% (10 of 42 mild to moderate hemorrhage and 2 of 42 vascular compromise to adjacent liver lobe). Dogs with right-sided liver tumors are more likely to have surgical complications caused by the proximity to the caudal vena cava. The median survival time for dogs undergoing surgery was
greater than 4 years. Tumor recurrence is rare and reported to be 0% to 13% after liver lobectomy. Dogs not undergoing surgical resection (N = 6) had a median survival time of 270 days with five of six dogs dying because of progressive disease. The metastatic rate for hepatocellular carcinoma ranges from 4.8% to 61%. The morphologic type and histopathologic features influence biologic behavior. In one report 100% of the diffuse type, 93% of the nodular type, and 37% of the massive type had metastatic disease at necropsy. Early detection may also influence the rate of metastasis because the lowest rate was from a report on dogs that underwent curative intent surgery. The most common sites of metastasis are local lymph nodes, lung, and peritoneum. Data on cats with hepatocellular carcinoma are limited; in one report two of eight cats had metastatic disease at necropsy.

**Bile Duct Tumors**

Bile duct adenomas are benign tumors derived from biliary epithelium. They are rarely documented in dogs. Bile duct adenocarcinomas occur more commonly and behave aggressively with metastasis documented in 60% to 88% of necropsy cases. The most common sites of metastasis are local lymph nodes and lungs with other abdominal organs and bone reported less frequently. In cats benign bile duct adenomas (also referred to as “biliary adenomas,” “biliary cystadenomas,” or “cholangiocellular adenomas”) are the most common hepatobiliary tumor followed by bile duct adenocarcinomas (cholangiocarcinomas). As in dogs, carcinomas of the biliary system behave aggressively in cats with metastasis detected in 80% in one report; in another report all 10 cats with bile duct carcinomas died or were euthanized during hospitalization. Bile duct tumors that are solitary or confined to one liver lobe with no evidence of lymph node or distant metastasis should be surgically excised. Effective chemotherapy agents have not been identified.

**Neuroendocrine Tumors (carcinoids)**

In dogs hepatic neuroendocrine tumors are uncommon and typically have a diffuse morphology making surgical excision rarely an option. Effective therapy remains to be determined. A few case reports have documented neuroendocrine tumors of the gallbladder in dogs. All dogs seemed to have localized disease and had cholecystectomies performed. Long-term follow-up is lacking but one dog lived 8 months before recurrent gastrointestinal signs developed and another lived 10 months without evidence of recurrent disease before being lost to follow-up. Neuroendocrine
tumors in cats can be intrahepatic or extrahepatic involving the bile duct and rarely involve the gallbladder. One cat with a composite tumor (elements of both epithelial and neuroendocrine carcinoma) lived for over a year before dying of another unrelated tumor, and two cats with extrahepatic tumors lived for over a year before being lost to follow-up. The remaining 14 cats were euthanized during or soon after surgery. Four cats underwent necropsies; all had metastatic disease. Sites of metastasis included lymph nodes, lungs, and intestine, and all had carcinomatosis.

**Sarcomas**

Hepatic sarcomas make up less than 13% of primary hepatic tumors in the dog. Hemangiosarcoma, leiomyosarcoma, fibrosarcoma, osteosarcoma, malignant mesenchymoma, and chondrosarcoma have been reported. Primary sarcomas of the liver tend to behave aggressively having either a diffuse morphology or metastatic disease at diagnosis (Fig. 4).

Primary sarcomas of the liver are also rare in cats. Case reports and case series have documented hemangiosarcoma, leiomyosarcoma, rhabdomyosarcoma, and osteosarcoma. Most cats with hemangiosarcoma had metastatic disease at diagnosis. A cat with a primary extraskeletal hepatic osteosarcoma was treated with surgery and carboplatin and was alive 42 months after diagnosis with no clinical evidence of disease.

**Lymphoma**

Lymphoma is a common neoplasia in both dogs and cats. In dogs the liver can be involved in variable forms including multicentric, alimentary, or hepatosplenic lymphoma. A study in cats documented that abdominal lymphoma is currently the most common anatomic location and the liver occasionally is the only organ involved. Low-grade lymphocytic lymphoma affects the intestinal tract of older, feline leukemia virus negative cats and has a better prognosis than high-grade lymphoma. In two reports the liver was involved in 20% to 24% of cats with
lymphocytic lymphoma, although the number of cats that had liver biopsies was small so the true extent of liver involvement is unknown. Median survival times are reported to be 2 years or more with prednisone and chlorambucil chemotherapy. Studies are ongoing to determine if some of the inflammatory liver diseases in cats are small cell lymphocytic lymphoma (Sharon Center, personal communication, 2008). Another type of lymphoma that often affects the liver of cats is lymphoma of large granular lymphocytes, which is thought to originate in the small intestine. Hepatomegaly was documented in 80% of cats in one study and 12 of 13 had histologic confirmation of lymphoma in the liver. Alanine aminotransferase and total bilirubin were increased in 7 of 12 and 7 of 13 cats respectively.

The best treatment to date for high-grade lymphomas in dogs and cats is a combination protocol that contains doxorubicin, vincristine, cyclophosphamide, and prednisone. Careful evaluation of liver function is necessary before starting chemotherapy because many drugs undergo hepatic metabolism and altered hepatic clearance may lead to unpredictable and potentially increased toxicity.

**Histiocytic Sarcoma**

Disseminated histiocytic sarcoma of dogs frequently involves the liver and other organs. CCNU has shown some efficacy with 46% of dogs responding with a median remission duration of 85 days and median survival time of 172 days.

**Mast Cell Tumors**

Mast cell tumors can metastasize to the liver of dogs in advanced disease and rarely have been implicated as the primary site. The overall prognosis of dogs with disseminated mast cell tumor is grave. The median survival times reported in one study was 43 days despite therapy with various chemotherapy agents. Chemotherapeutic drugs most active against mast cell tumors include vinblastine and lomustine. Recently, tyrosine kinase inhibitors have shown some promise. Primary visceral mast cell tumors are more common in cats than dogs. The spleen is usually the primary site with metastasis to the liver and bone marrow common. Survival time with splenectomy alone can be a year or more. Recently, lomustine (CCNU) has been shown to be active against feline mast cell tumors.

![Primary hepatic anaplastic sarcoma in a dog. (Courtesy of James Flanders, Ithaca, NY.)](image)
SUMMARY

Hepatobiliary tumors are uncommon in dogs and cats. They generally occur in older animals with nonspecific clinical signs usually relating to the gastrointestinal tract. Liver enzyme concentrations are commonly elevated. Early detection for massive-type lesions may allow for surgical resection and prolonged survival especially for hepatocellular carcinomas. Chemotherapy, in general, is not effective for primary liver tumors.

REFERENCES


